Quick synthesis of a novel combinatorial delivery system of siRNA and doxorubicin for a synergistic anticancer effect

References

• Konieczkowski DJ, Johannessen CM, Garraway LA. A convergence-based framework for cancer drug resistance. Cancer Cell. 2018;33(5):801–815. doi:10.1016/j.ccell.2018.03.02529763622
   PubMed Web of Science ®Google Scholar
• Bar-Zeev M, Livney YD, Assaraf YG. Targeted nanomedicine for cancer therapeutics: towards precision medicine overcoming drug resistance. Drug Resist Updat. 2017;31:15–30. doi:10.1016/j.drup.2017.05.00228867241
   PubMed Web of Science ®Google Scholar
• Li Y, Gao X, Yu Z, et al. Reversing multidrug resistance by multiplexed gene silencing for enhanced breast cancer chemotherapy. ACS Appl Mater Interfaces. 2018;10(18):15461–15466. doi:10.1021/acsami.8b0280029663807
   PubMed Web of Science ®Google Scholar
• Meng H, Mai WX, Zhang H, et al. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. ACS Nano. 2013;7(2):994–1005. doi:10.1021/nn305697q23289892
   PubMed Web of Science ®Google Scholar
• Kanasty R, Dorkin JR, Vegas A, Anderson D. Delivery materials for siRNA therapeutics. Nat Mater. 2013;12(11):967–977. doi:10.1038/nmat376524150415
   PubMed Web of Science ®Google Scholar
• Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8(2):129–138. doi:10.1038/nrd299819180106
   PubMed Web of Science ®Google Scholar
• Xu X, Wu J, Liu Y, et al. Multifunctional envelope-type siRNA delivery nanoparticle platform for prostate cancer therapy. ACS Nano. 2017;11(3):2618–2627. doi:10.1021/acsnano.6b0719528240870
   PubMed Web of Science ®Google Scholar
• Chen Y, Wang X, Zhang DS, Gu H. Highly effective antiangiogenesis via magnetic mesoporous silica-based siRNA vehicle targeting the VEGF gene for orthotopic ovarian cancer therapy. Int J Nanomed. 2015;10:2579–2594.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Kim A, Miyata K, Kataoka K. Recent progress in development of siRNA delivery vehicles for cancer therapy. Adv Drug Deliv Rev. 2016;104:61–77. doi:10.1016/j.addr.2016.06.01127352638
   PubMed Web of Science ®Google Scholar
• Chen Y, Gu H, Zhang DS-Z, et al. Highly effective inhibition of lung cancer growth and metastasis by systemic delivery of siRNA via multimodal mesoporous silica-based nanocarrier. Biomaterials. 2014;35(38):10058–10069. doi:10.1016/j.biomaterials.2014.01.02625277774
   PubMed Web of Science ®Google Scholar
• Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017;23(10):1124–1134. doi:10.1038/nm.426528985214
   PubMed Web of Science ®Google Scholar
• Wang D, Xu X, Zhang K, et al. Codelivery of doxorubicin and MDR1-siRNA by mesoporous silica nanoparticles-polymerpolyethylenimine to improve oral squamous carcinoma treatment. Int J Nanomed. 2018;13:187–198. doi:10.2147/IJN.S177627
   PubMed Web of Science ®Google Scholar
• Kwak G, Jo SD, Kim D, et al. Synergistic antitumor effects of combination treatment with metronomic doxorubicin and VEGF-targeting RNAi nanoparticles. J Control Release. 2017;267:203–213. doi:10.1016/j.jconrel.2017.08.01528823674
   PubMed Web of Science ®Google Scholar
• Han L, Huang R, Li J, Liu S, Huang S, Jiang C. Plasmid pORF-hTRAIL and doxorubicin co-delivery targeting to tumor using peptide-conjugated polyamidoamine dendrimer. Biomaterials. 2011;32(4):1242–1252. doi:10.1016/j.biomaterials.2010.09.07020971503
   PubMed Web of Science ®Google Scholar
• Huang S, Shao K, Liu Y, et al. Tumor-targeting and microenvironment-responsive smart nanoparticles for combination therapy of antiangiogenesis and apoptosis. ACS Nano. 2013;7(3):2860–2871. doi:10.1021/nn305697q23451830
   PubMedGoogle Scholar
• Jeong H, Lee SH, Hwang Y, et al. Multivalent aptamer-RNA conjugates for simple and efficient delivery of doxorubicin/siRNA into multidrug-resistant cells. Macromol Biosci. 2017;17:4. doi:10.1002/mabi.201700070
   Web of Science ®Google Scholar
• Bagalkot V, Farokhzad OC, Langer R, Jon S. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem Int Ed Engl. 2006;45(48):8149–8152. doi:10.1002/anie.20060225117099918
   PubMed Web of Science ®Google Scholar
• Han L, Jin C, Liu B, Che S. DNA-silica mineralization: the formation of exceptional two dimensional-square p4mm symmetry by a structural transformation. Chem Mater. 2012;24(3):504–511. 10.1021/cm202874w.
   Google Scholar
• Che S, Garcia-Bennett AE, Yokoi T, et al. A novel anionic surfactant templating route for synthesizing mesoporous silica with unique structure. Nat Mater. 2003;2(12):801–805. doi:10.1038/nmat102214634644
   PubMedGoogle Scholar
• Liu B, Yao Y, Che S. Template-assisted self-assembly: alignment, placement, and arrangement of two-dimensional mesostructured DNA-silica platelets. Angew Chemie. 2013;125(52):14436–14440. doi:10.1002/ange.201307897
   Google Scholar
• Jin C, Qiu H, Han L, Shu M, Che S. DNA transcription into diverse porous silicas by a co-structure directing route: chiral, ring and ordered nanochannel arrays. Chem Commun (Camb). 2009;23:3407–3409. doi:10.1039/b900614a
   Google Scholar
• He C, Hu Y, Yin L, Tang C, Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials. 2010;31(13):3657–3666. doi:10.1016/j.biomaterials.2010.01.04220138662
   PubMed Web of Science ®Google Scholar
• Chen AM, Zhang M, Wei D, et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small. 2009;5(23):2673–2677. doi:10.1002/smll.20090062119780069
   PubMed Web of Science ®Google Scholar
• Tang F, Li L, Chen D. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv Mater. 2012;24:1504–1534. doi:10.1002/adma.20110476322378538
   PubMed Web of Science ®Google Scholar
• Lu J, Liong M, Li Z, Zink JI, Tamanoi F. Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small. 2010;6(16):1794–1805. doi:10.1002/smll.20100053820623530
   PubMed Web of Science ®Google Scholar
• Jain A, Barve A, Zhao Z, Jin W, Cheng K. Comparison of avidin, neutravidin, and streptavidin as nanocarriers for efficient siRNA delivery. Mol Pharm. 2017;14(5):1517–1527. doi:10.1021/acs.molpharmaceut.6b0093328026957
   PubMed Web of Science ®Google Scholar
• Zhao Z, Li Y, Jain A, et al. Development of a peptide-modified siRNA nanocomplex for hepatic stellate cells. Nanomedicine. 2018;14(1):51–61. doi:10.1016/j.nano.2017.08.01728890106
   PubMed Web of Science ®Google Scholar
• Shukla RS, Jain A, Zhao Z, Cheng K. Intracellular trafficking and exocytosis of a multi-component siRNA nanocomplex. Nanomedicine. 2016;12(5):1323–1334. doi:10.1016/j.nano.2016.02.00326970028
   PubMed Web of Science ®Google Scholar
• Wojnilowicz M, Glab A, Bertucci A, Caruso F, Cavalieri F. Super-resolution imaging of proton sponge-triggered rupture of endosomes and cytosolic release of siRNA. ACS Nano. 2019;13(1):187–202. 10.1021/acsnano.8b05151.
   PubMedGoogle Scholar
• Xiong XB, Lavasanifar A. Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin. ACS Nano. 2011;5(6):5202–5213. doi:10.1021/nn202666w21627074
   PubMed Web of Science ®Google Scholar
• Creixell M, Peppas NA. Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance. Nano Today. 2012;7(4):367–379. doi:10.1016/j.nantod.2012.06.01326257819
   PubMed Web of Science ®Google Scholar